What is Noble Financial’s Forecast for GLSI FY2025 Earnings?

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) – Noble Financial lowered their FY2025 earnings per share estimates for Greenwich LifeSciences in a research note issued on Wednesday, December 10th. Noble Financial analyst R. Leboyer now expects that the company will post earnings per share of ($1.30) for the year, down from their prior estimate of ($1.25). Noble Financial has a “Outperform” rating and a $45.00 price target on the stock. The consensus estimate for Greenwich LifeSciences’ current full-year earnings is ($0.80) per share.

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Greenwich LifeSciences in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Greenwich LifeSciences presently has a consensus rating of “Hold” and a consensus price target of $42.00.

Greenwich LifeSciences Trading Down 4.8%

GLSI stock opened at $10.73 on Friday. The stock’s 50 day simple moving average is $9.20 and its 200 day simple moving average is $10.20. Greenwich LifeSciences has a 12-month low of $7.78 and a 12-month high of $14.47. The firm has a market cap of $148.61 million, a P/E ratio of -7.35 and a beta of 1.61.

Greenwich LifeSciences (NASDAQ:GLSI) last released its earnings results on Friday, November 14th. The company reported ($0.30) EPS for the quarter, hitting analysts’ consensus estimates of ($0.30).

Insider Transactions at Greenwich LifeSciences

In other news, CEO Snehal Patel bought 10,600 shares of the business’s stock in a transaction on Friday, November 7th. The stock was purchased at an average price of $8.43 per share, with a total value of $89,358.00. Following the transaction, the chief executive officer directly owned 5,583,502 shares in the company, valued at approximately $47,068,921.86. The trade was a 0.19% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last quarter, insiders have acquired 17,500 shares of company stock valued at $149,158. Company insiders own 51.47% of the company’s stock.

Hedge Funds Weigh In On Greenwich LifeSciences

Large investors have recently made changes to their positions in the business. Police & Firemen s Retirement System of New Jersey bought a new stake in Greenwich LifeSciences during the 2nd quarter valued at approximately $25,000. Bank of America Corp DE lifted its holdings in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares during the last quarter. Rhumbline Advisers boosted its position in shares of Greenwich LifeSciences by 48.7% in the first quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after acquiring an additional 3,168 shares during the period. HighTower Advisors LLC acquired a new stake in shares of Greenwich LifeSciences in the first quarter worth $147,000. Finally, Strs Ohio acquired a new stake in shares of Greenwich LifeSciences in the first quarter worth $177,000. Institutional investors and hedge funds own 4.16% of the company’s stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.